Dr. Reddy's Lab is poised to witness crosswinds from a drop in revenue from the patent expiration of Revlimid and increased ...

Dr. Reddy's Laboratories Ltd. closed 16.92% below its 52-week high of 1,420.20 rupees, which the company reached on August ...

CEO of Dr Reddy's Laboratories, Erez Israeli believes his company's affordable medicines benefit the U.S. market and will be ...

Dr. Reddy's Laboratories Ltd. 500124 shares slipped 2.23% to 1,197.40 Indian rupees Monday, on what proved to be an ...

Stay up-to-date with the Dr Reddys Stock Liveblog, your comprehensive source for real-time updates and detailed analysis on a prominent stock. Explore the latest information on Dr Reddys, including: ...

Welcome to the Dr Reddys Stock Liveblog, your ultimate source for real-time updates and analysis of one of the most prominent ...

Dr Reddy's Laboratories Ltd (RDY) reports a robust 16% YoY revenue growth, driven by strategic product launches and market ...

Dr Reddy's Laboratories (DRL) share price plunged 6.66 per cent to Rs 1,203.50 per share on the NSE during Friday after ...

Barclays analyst Balaji Prasad maintained a Buy rating on Dr Reddy’s Laboratories (RDY – Research Report) today and set a price target of ...

Dr. Reddy's Laboratories Ltd (NYSE:RDY) stock is trading lower after the company released third-quarter 2025 earnings. The pharma company clocked a net income of $165 million, marginally up from $161 ...

Crossmark Global Holdings Inc. grew its stake in shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY – Free Report) by 328.3% in the fourth quarter, Holdings Channel reports. The firm owned 12,760 ...

Pharmaceutical major Dr Reddy's Laboratories Ltd on Thursday (January 23) reported a 2.5% year-on-year (YoY) increase in net ...